Is Vyvanse for ADHD? Uses, Side Effects & Costs

Vyvanse (lisdexamfetamine dimesylate) is an FDA-approved stimulant medication for treating ADHD in children, adolescents, and adults. It is also the only stimulant approved to treat moderate-to-severe binge eating disorder, which makes it unusual among ADHD medications. What sets Vyvanse apart from older amphetamine formulations is its prodrug design: the drug is pharmacologically inactive until your body converts it into its active form, which shapes everything from how long it lasts to how likely it is to be misused.

How Vyvanse Works in the Body

Lisdexamfetamine is essentially d-amphetamine bonded to an amino acid called lysine. In that bonded form, it does nothing. Once you swallow a capsule, the drug passes through the gut intact and enters the bloodstream, where enzymes inside red blood cells gradually snip off the lysine and release active d-amphetamine.¹ That conversion happens at a relatively steady pace. In laboratory experiments, about half of the prodrug was broken down after four hours when incubated with the cytosolic extract of red blood cells, while in plasma alone the drug stayed completely stable and no active amphetamine appeared.¹

This built-in rate limiter gives Vyvanse a smoother pharmacokinetic profile than immediate-release amphetamine. The peak blood level of d-amphetamine is lower and takes longer to arrive, and there is less variation from dose to dose and person to person.² In practical terms, the therapeutic effect extends to at least 13 hours in children and 14 hours in adults, which is longer than what has been reported for other long-acting stimulant formulations.² For many people, that means a single morning dose covers the entire working or school day without needing a booster in the afternoon.

How Well Vyvanse Works for ADHD

Across multiple short-term trials in children, adolescents, and adults, Vyvanse has consistently outperformed placebo in reducing ADHD symptoms. In a randomized trial of adolescents, all three tested doses (30, 50, and 70 mg per day) produced significantly greater improvement than placebo on standard ADHD rating scales, and about 69% of participants on Vyvanse were rated as “much improved” or “very much improved” compared with roughly 40% on placebo.³ Longer-term data in adolescents showed that improvements held up, with about 87% rated as improved after extended treatment.⁴

In adults, the picture is similar. Three short-term trials showed that Vyvanse produced significantly greater improvements than placebo not just in core ADHD symptoms but also in executive functioning and quality of life.⁵ An open-label adult study found that after four weeks, nearly 79% of participants showed reliable improvement on a measure of executive function.⁶ Executive functioning covers things like organizing tasks, managing time, and sustaining attention on boring work. These are the day-to-day struggles that often bother adults with ADHD more than the hyperactivity component.

How Vyvanse Compares to Other ADHD Medications

A large network meta-analysis published in The Lancet Psychiatry, which pooled evidence across many trials, found that amphetamine-based medications (the class Vyvanse belongs to) were more effective than methylphenidate, atomoxetine, and modafinil in both children and adults based on clinician-rated outcomes.⁷ That does not mean amphetamines are the right first choice for everyone, since tolerability and individual response vary, but it does place Vyvanse’s drug class at the top of the efficacy rankings.

In a head-to-head trial against atomoxetine (Strattera), which is a non-stimulant ADHD medication, Vyvanse produced a faster clinical response. The median time to first response was 12 days for Vyvanse versus 21 days for atomoxetine, and by week nine, about 82% of Vyvanse patients had responded compared with roughly 64% on atomoxetine.⁸ The rate of side effects was similar between the two drugs in that trial. For people who cannot tolerate stimulants or have reasons to avoid them, atomoxetine and other non-stimulants remain reasonable options, but Vyvanse tends to work faster and for more people.

A separate network meta-analysis focused on children and adolescents noted that while Vyvanse ranked well for efficacy, it was also more likely than some alternatives to cause appetite loss, sleep problems, and irritability.⁹ That trade-off between stronger symptom control and a more noticeable side-effect profile is the central tension most prescribers and patients navigate.

Side Effects to Expect

The most common side effects of Vyvanse are the ones you would expect from any amphetamine: decreased appetite, dry mouth, trouble sleeping, and headache. In the pivotal binge eating disorder trials, which used the same drug at similar doses, the side effects reported by more than one in ten participants on Vyvanse were dry mouth, headache, and insomnia.¹⁰ Most people who continue treatment find these manageable, though appetite suppression can be persistent enough to warrant attention, especially in children.

Growth in Children and Adolescents

A legitimate concern for parents is whether long-term stimulant use will affect their child’s growth. A study tracking children on Vyvanse found that they continued to grow in height, but their gains in height, weight, and BMI were smaller than what would be expected from age-matched norms. The effect was most pronounced in children who were heavier or taller at baseline and in those who had never taken a stimulant before.¹¹ A two-year open-label study found a similar pattern: average weight and height z-scores (a way of comparing growth to the population average) decreased during the first nine months or so of treatment and then stabilized.¹² The children did not shrink, but they gained weight and height more slowly than their untreated peers. Most pediatricians monitor growth at regular intervals and may suggest drug holidays during summers or other breaks to allow catch-up growth.

Cardiovascular Concerns

Stimulant medications cause small but real increases in heart rate and blood pressure across all age groups.¹³ Understandably, this has fueled worry about serious cardiac events. The accumulated evidence, though, suggests that the risk of sudden cardiac death or major cardiovascular problems at therapeutic doses is extremely low, and that the benefits of treating ADHD outweigh those risks for the vast majority of patients.¹³ A large population-based cohort study in Denmark and Sweden specifically looked at Vyvanse users and found little to no increased risk of major cardiovascular or cerebrovascular events compared with people previously treated with other ADHD medications.¹⁴ A baseline cardiovascular screening before starting the medication is standard practice, but routine EKGs are not recommended for every patient unless there is a known heart condition or family history of sudden cardiac death.

Psychosis

In rare cases, stimulant medications have been linked to the emergence of psychotic symptoms such as hallucinations or paranoia. A published case report describes a 13-year-old with autism spectrum disorder and ADHD who developed abrupt psychosis about a week after starting Vyvanse.¹⁵ This is worth knowing about, but it is genuinely rare and usually resolves once the drug is stopped. Prescribers typically ask about any personal or family history of psychotic disorders before writing the prescription.

Abuse Potential and the Prodrug Advantage

All amphetamine-based medications carry Schedule II status, meaning the government considers them to have significant abuse potential. Vyvanse was specifically designed to mitigate that risk. Because the drug has to be enzymatically converted inside the body, crushing it and snorting or injecting it does not produce the rapid, intense high that users seek from immediate-release amphetamine. Clinical and preclinical studies have consistently found that Vyvanse produces a slower onset of effects and a lower peak of euphoria compared with immediate-release dexamphetamine, and its prodrug property limits the ability to extract a quicker hit through non-oral routes.¹⁶

That said, “lower abuse potential” is not the same as “no abuse potential.” Vyvanse still delivers d-amphetamine to the brain, and people can and do misuse it by taking larger oral doses than prescribed. The prodrug design reduces, but does not eliminate, risk. It is one of the reasons some prescribers prefer Vyvanse over other amphetamine formulations for patients with a history of substance use, though the decision is always individualized.

Vyvanse for Binge Eating Disorder

In 2015, Vyvanse became the first and, as of now, only medication approved by the FDA for treating moderate-to-severe binge eating disorder in adults. This is not an off-label quirk; it went through its own dedicated trial program. Two pivotal phase 3 trials showed large reductions in binge eating days per week compared with placebo, with effect sizes in the range of 0.83 to 0.97, which is considered large by clinical standards.¹⁰ In an earlier dose-finding trial, half of participants on the 70 mg dose achieved complete cessation of binge eating over a four-week period, compared with about one in five on placebo.¹⁷

A meta-analysis pooling three trials confirmed that Vyvanse significantly outperformed placebo on binge eating days, symptom severity scores, and both response and remission rates. However, it also found that participants on Vyvanse were roughly twice as likely to discontinue due to side effects as those on placebo.¹⁸ The drug is not approved for weight loss, and prescribing it solely for that purpose is inappropriate. Its benefit in binge eating disorder is tied to reducing the compulsive drive to binge, not just to appetite suppression.

What About Depression?

You may have heard that stimulants can help with treatment-resistant depression. Early interest led to several clinical trials testing Vyvanse as an add-on to antidepressants. The results were disappointing. A meta-analysis of four randomized controlled trials found that Vyvanse did not outperform placebo on depression rating scales, and it did not significantly improve remission or response rates either. Meanwhile, participants in the Vyvanse group had about a 10% higher chance of experiencing side effects.¹⁹ If you have both ADHD and depression, treating the ADHD with Vyvanse may indirectly improve your mood by giving you back the ability to function, but the evidence does not support using Vyvanse as a depression treatment in its own right.

Costs and the Generic Landscape

For years, Vyvanse’s biggest practical barrier was cost. As a brand-name medication with patent protection, it routinely cost several hundred dollars per month without insurance. The patent expired in the second half of 2023, and generic lisdexamfetamine entered the market. In theory, this should have made the drug much cheaper. In practice, the rollout was bumpy. Production of brand-name Vyvanse dropped sharply when the patent expired, and while generic production jumped to fill the gap, there was an abrupt decline in generic supply shortly after, likely related to shortages of active ingredient and DEA production quotas.²⁰ The DEA subsequently raised its production quota for lisdexamfetamine for 2024.²⁰

Generic availability has improved since then, and many pharmacies now carry one or more generic versions. The price varies by pharmacy, insurance plan, and dose, but generics typically cost a fraction of what brand-name Vyvanse did. If your pharmacy tells you a generic is on backorder, it is worth checking other nearby pharmacies or asking your prescriber about alternative lisdexamfetamine manufacturers. The broader ADHD medication shortage has affected multiple stimulants at various times, not just Vyvanse, so supply disruptions remain an ongoing frustration for patients.

Sticking With Treatment

One often-overlooked aspect of ADHD treatment is persistence: how long people actually stay on their medication before switching or stopping. A large retrospective analysis found that both children and adults who started on Vyvanse had a lower rate of discontinuation compared with most other ADHD treatments. In adults, the difference was statistically significant compared with nearly every comparator group.²¹ This makes intuitive sense: if a once-daily medication covers 13 to 14 hours with a smooth onset and offset, there is less reason to switch. In a separate survey of over 1,200 ADHD patients, the most common reasons for changing medications were lack of rapid onset and insufficient duration of effect, both areas where Vyvanse’s pharmacokinetics perform relatively well.²²

Pregnancy and Breastfeeding

This is an area where the evidence is thin and the guidance cautious. Animal studies have shown adverse effects at high amphetamine doses, and no large controlled trials in pregnant women exist for obvious ethical reasons. A case report documented one woman who took lisdexamfetamine during her second pregnancy and reported significantly better mental well-being than during her first (unmedicated) pregnancy, though both pregnancies had similar courses and fetal outcomes, including preterm delivery and neonatal complications.²³ A single case report cannot tell us much about population-level risk, but it illustrates the reality that some women and their doctors decide the benefits of continuing medication outweigh the uncertain risks.

Breastfeeding presents its own questions. Amphetamines do pass into breast milk. A small pilot study that followed 13 children exposed to amphetamine stimulants through breastfeeding found normal neurodevelopment and no significant adverse effects, leading the researchers to suggest that amphetamines are likely compatible with breastfeeding, though they emphasized the need for larger studies.²⁴ An older review, however, concluded that breastfeeding with amphetamines should be considered contraindicated due to the drug’s presence in infant blood at potentially concerning concentrations.²⁵ The disagreement between these sources reflects the genuine uncertainty in the field. The safest path is a careful conversation with both your psychiatrist and your obstetrician or pediatrician, weighing the severity of your ADHD symptoms against the limited and conflicting safety data. For many women, stopping medication during pregnancy and breastfeeding is the default recommendation, but it is not the only medically defensible choice.

Vyvanse Beyond ADHD in Healthy Adults

An intriguing line of research has explored whether Vyvanse can help healthy adults who develop executive function difficulties, particularly menopausal women who report new cognitive complaints such as difficulty organizing, planning, and staying focused. A neuroimaging study found that Vyvanse treatment was associated with decreased symptom severity and measurable changes in brain activation patterns in menopausal women with midlife-onset executive difficulties.²⁶ This research is in early stages and does not support prescribing Vyvanse off-label for menopause-related cognitive complaints. But it hints at why so many people without a formal ADHD diagnosis are curious about stimulants: the executive function improvements are real and appealing even outside the clinical ADHD population. Whether extending stimulant use to broader groups is wise, or would simply medicalize normal cognitive variation, is a debate the field has not resolved.